Navigating a metastatic castration-resistant prostate cancer (mCRPC) diagnosis while preserving self-identity can feel like ...

Led by former Novartis executive Emanuele Ostuni, the startup has a prostate cancer medicine advancing into early clinical ...

Q2 2025 Earnings Call Transcript July 21, 2025 Operator: Good morning and good afternoon, and welcome to the Novartis Q2 2025 ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Novartis AG stands third among the most undervalued ...

Key Points President Trump's tariffs could erode healthcare companies' profits, but some may perform well regardless.Eli ...

Once seen as a niche tool for rare tumors, theranostics is quickly becoming a new standard in cancer care. Combining diagnostics and therapy in a single platform, the field has drawn billions in ...

Novartis AG (NVS) reports robust sales and income growth, announces a $10 billion share buyback, and navigates competitive ...

While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

Company touted Kisqali's "replacement power" as another blockbuster faces generic competition and expressed optimism about ...

Swiss drugmaker Novartis nudged up its full-year earnings forecast on Thursday, citing strong second-quarter sales of key drugs such as Kisqali, and said potential new U.S. tariffs would not ...

As new drug launches such as Pluvicto in prostate cancer accelerate, Novartis is opening a $10 billion share buyback to be completed by year-end 2027.

Novartis NOVN -0.39% launched a share buyback of up to $10 billion and raised its full-year profit guidance after continued demand for key drugs fueled growth in second-quarter sales and earnings.